Oncolytics Biotech Inc. Files 6-K
Ticker: ONCY · Form: 6-K · Filed: Jan 15, 2025 · CIK: 1129928
Sentiment: neutral
Topics: reporting, sec-filing, foreign-private-issuer
Related Tickers: ONCY
TL;DR
ONCOLYTICS BIOTECH INC. (ONCY) filed a 6-K, confirming 20-F annual report filing.
AI Summary
Oncolytics Biotech Inc. filed a Form 6-K on January 15, 2025, reporting as a foreign private issuer. The company is based in Calgary, Alberta, Canada, and operates in the Pharmaceutical Preparations industry. This filing indicates they will file annual reports under Form 20-F.
Why It Matters
This filing provides an update on Oncolytics Biotech Inc.'s reporting status and confirms their adherence to SEC regulations for foreign private issuers.
Risk Assessment
Risk Level: low — This is a routine administrative filing by a foreign private issuer and does not contain new financial or operational information that would typically increase risk.
Key Players & Entities
- ONCOLYTICS BIOTECH INC (company) — Filer
- January 2025 (date) — Reporting period
- 001-38512 (other) — SEC File Number
- Calgary, Alberta, Canada (location) — Company headquarters
- Form 20-F (document) — Annual report filing type
- Form 6-K (document) — Filing type
FAQ
What is the primary purpose of this Form 6-K filing?
The Form 6-K is filed by Oncolytics Biotech Inc. as a report of a foreign private issuer for the month of January 2025, indicating their reporting status and adherence to SEC regulations.
Where is Oncolytics Biotech Inc. headquartered?
Oncolytics Biotech Inc. is headquartered in Calgary, Alberta, Canada.
Which form will Oncolytics Biotech Inc. use for its annual reports?
Oncolytics Biotech Inc. will file its annual reports under cover of Form 20-F.
What is the SEC file number for Oncolytics Biotech Inc.?
The SEC file number for Oncolytics Biotech Inc. is 001-38512.
Does this filing indicate submission in paper format?
The filing includes an indication for submission in paper as permitted by Regulation S-T Rule 101(b)(1), but it is not checked, suggesting it is not being submitted in paper.
Filing Stats: 334 words · 1 min read · ~1 pages · Grade level 17.1 · Accepted 2025-01-15 09:27:38
Filing Documents
- form6kgobletc5pei.htm (6-K) — 18KB
- oncypeic5.htm (EX-99.1) — 24KB
- 0001129928-25-000002.txt ( ) — 43KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Oncolytics Biotech Inc. (Registrant) By s Kirk Look Date January 15, 2025 Kirk Look Chief Financial Officer